pharmaphorum

JUNE 27, 2022

It is also approved for patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete surgical removal, and is in phase 3 testing as a combination therapy with rituximab and lenalidomide as a second-line therapy for FL. Ipsen’s CVR offer includes $0.30

Biopharma 110

Biopharma Sales Prescription FDA 110

European Pharmaceutical Review

NOVEMBER 12, 2024

To boost AstraZeneca’s research and manufacturing footprint by the end of 2026, it is dedicating $3.5 Overall, the biopharma firm explained that these initial US investments are part of AstraZeneca’s plan to attain $80 billion in Total Revenue by the end of the decade. billion of capital investment in the US.

Manufacturing 59

Manufacturing Biopharma Healthcare Healthcare 59

European Pharmaceutical Review

APRIL 18, 2023

GSK has agreed to acquire late-stage biopharma BELLUS Health, for a total of £1.6 It is estimated that 28 million patients suffer from chronic cough, with 10 million patients globally and six million in the US and European Union (EU) suffering from RCC for over a year, according to a 2015 study. per share in cash.

Biopharma 98

Biopharma Sales Patients Medical 98

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. starting new lung cancer patients on LIBTAYO® or melanoma patients on Opdualag instead of KEYTRUDA®).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

APRIL 24, 2023

Health systems will buy or establish an insurance plan to serve as an extension of their continuum of care, a means of directing referral streams to increase revenue and securing control over clinical and formulary decisions for patients.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Pharmaceutical Technology

JANUARY 31, 2023

Inflation Reduction Act Speaking during the keynote panel “FDA & ARPA-H: Life Sciences, Biopharma & Medtech Priorities in a New Year”, Califf discussed the Inflation Reduction Act of August 2022, which aims to lower prescription drug prices.

FDA 52

FDA Prescription Medicine Biopharma 52

Clarivate

AUGUST 20, 2024

Price negotiations will be staggered over time, beginning with this initial list of ten Part D drugs that takes effect in 2026 (Part D is the prescription drug coverage component of Medicare, a federal health insurance program for people 65 and older which covers nearly 1 in 5 Americans). These ten drugs cost Medicare Part D nearly $46.8

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52